Department of Surgery

Matthew D. Neal, MD, FACS

  • Professor of Surgery and Watson Fund in Surgery Chair
  • Vice Chair of Surgery, Academic Training
  • Director of Emergency General Surgery
  • Co-Director, Pittsburgh Trauma and Transfusion Medicine Research Center
  • Professor of Clinical and Translational Science and Critical Care Medicine (secondary appointments)

Education & Training

  • BS, Georgetown University
  • MD, University of Pittsburgh School of Medicine
  • General Surgery Residency, UPMC
  • Pediatric Surgery Research Fellowship, Children’s Hospital of Pittsburgh of UPMC
  • Surgical Critical Care Fellowship, UPMC

Representative Publications

Dr. Neal's publications can be reviewed through NCBI.

Research, Clinical, and/or Academic Interests

  • Co-lead for the coordinating center for the NIH-sponsored Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV-4) program; Co-chair, Inpatient Anti-Thrombotics for COVID-19 clinical trial
  • Trauma-induced coagulopathy and hemostasis following trauma and hemorrhagic shock 
  • Measurement of coagulopathy in trauma and sepsis 
  • Clinical outcomes in trauma/hemorrhagic shock 
  • Clinical outcomes in massive transfusion 
  • Acute care surgery outcomes research and surgical rescue
  • Outcomes research focusing on emergency general surgery, elective abdominal wall reconstruction, and surgical rescue

Research Grants

  • PI: Endothelial Dysfunction and Restoration in Trauma Induced Coagulopathy  (R01 HL166944-01), NIH/NHLBI, 09/15/23-08/31/28
  • Site PI: DARPA CONCERT “Field Solutions for Hemorrhage with bio-Artificial Resuscitation Products (FSHARP)”, DARPA, 01/01/23-12/31/27
  • PI: Mechanistic Elucidation and Targeted Therapy of Platelet Dysfunction after Trauma (1R35GM119526-01 Maximizing Investigators’ Research Award (MIRA)), NIH/NIGMS, 08/01/16-07/31/21
  • PI: Mechanisms of platelet exosome-mediated acute chest syndrome in sickle cell disease (R01HL141080-01A1), NIH/NHLBI, 04/22/2019-03/31/2023          
  • Co-PI: Field-Deployable Dried Platelet Surrogate Nanotechnology for Hemorrhage Control in RDCR (Department of Defense), Department of Defense JPC-6 Combat Casualty Care Research Program, 04/01/2020-03/31/2023
  • Co-I: Dual role of HMGB1 in pathogenic platelet biology in pulmonary hypertension (R01HL130268-04), NHLBI, 3/1/19-2/28/22
  • Co-I: REVIVE:  Reducting Exsanguination Via In-Vivo Expandable Foam (Sperry), Arsenal Medical Inc.,12/1/18-11/30/20
  • Co-I: Engineering Biologic Topography into Vascular Grafts (R56HL142743), NIH/ NHLBI, 9/15/18-8/31/20
  • Co-I: Pragmatic, Prehospital Group O Whole Blood Early Resuscitation Pilot Trial R34 HL135224-01A1, NIH/NHLBI, 07/05/17-06/01/21
  • Co-I:  Linking Investigations in Trauma and Emergency Services (LITES) W81XWH-16-D-0024, Department of Defense, 2017- (Indefinite Delivery, Indefinite Quantity Contract)
  • PI: Testing for Platelet Inhibition before and after platelet transfusion in Traumatic Brain Injury (TPI-TBI), Accriva Diagnostics, 1/01/2018-12/31/2020
  • Site PI: Analysis and Characterization of Trauma-Induced Coagulopathy NIH UM1HL120877, NIH/NHLBI, 7/01/19 – 6/30/21

Faculty by divisions